Casinvent Pharma
CK1 inhibitors developer for solid and hematologic cancers.
1
Funding Rounds
$1.7m
Money raised
Overview
CK1 inhibitors developer for solid and hematologic cancers.
- Website:
- Headquarters: Brno
- Social accounts: linkedin
Funding series
Funding Series Analysis
The company Casinvent Pharma has raised a total of $1.7m in funding over 1 rounds.
Key Insights:
- Casinvent Pharma January 2024 Seed Funding Round: $1.7m
Casinvent Pharma January 2024 Seed Funding Round
$1.7m
Industries
Casinvent Pharma is active in the following industries: